Lille/Oslo, 9 June 2021

Reference is made to the stock exchange announcements of 18 May 2021 regarding
the completion of Compagnie des Levures Lesaffre's ("Lesaffre") mandatory offer
for all shares in NattoPharma ASA ("NattoPharma" or the "Company") not already
owned by Lesaffre (the "Offer").

Following completion of the Offer, Lesaffre currently owns 20,693,517 shares in
NattoPharma, representing 98.33% of the total shares and voting rights.

The Board of Directors of Lesaffre plan to resolve, effective from after close
of trading on Oslo Børs today, 9 June 2021, a compulsory acquisition of all
shares in NattoPharma not owned by Lesaffre, pursuant to the Norwegian Public
Limited Liability Companies Act section 4-25 cf. the Norwegian Securities
Trading Act section 6-22 (1). As a consequence, Lesaffre will assume ownership
of all shares in the Company.

The offered redemption price under the compulsory acquisition will be NOK 35.00
per share, which corresponds to the offer price in the Offer and, according to
the Norwegian Securities Trading Act section 6-22 (2), is the applicable
redemption price in a subsequent compulsory acquisition.

Following the compulsory acquisition, Lesaffre will pursue a de-listing of the
Company's shares from Euronext Expand. Separate stock exchange notices will be
published regarding the timing for such delisting.

Rothschild is acting as financial adviser to Lesaffre and Nordea Bank Abp,
filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is
acting as the Norwegian legal adviser, and Linklaters is acting as the French
legal adviser, to Lesaffre in connection with the Offer.

For further information, please contact:

NattoPharma:

NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:

Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr